Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 6/20 | 0.79 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.47 |
| ▸ | HTR7 | P34969 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18387792 | 0.95 | SLC7A11 (0.76) | SLC7A11VDAC2HIF1AHTR7ALDH1A1 | |
| SCHEMBL18387789 | 0.93 | SLC7A11 (0.81) | SLC7A11VDAC2HIF1AHTR7ALDH1A1 | |
| SCHEMBL14447223 | 0.92 | SLC7A11 (0.75) | SLC7A11VDAC2HIF1AHTR7ALDH1A1 | |
| SCHEMBL13633718 | 0.90 | SLC7A11 (0.89) | SLC7A11VDAC2HIF1AHTR7ALDH1A1 | |
| SCHEMBL4461445 | 0.90 | SLC7A11 (0.83) | SLC7A11VDAC2HIF1AHTR7ALDH1A1 | |
| SCHEMBL21134755 | 0.90 | SLC7A11 (0.76) | SLC7A11VDAC2HIF1AHTR7ALDH1A1 | |
| SCHEMBL25793246 | 0.89 | SLC7A11 (0.87) | SLC7A11VDAC2HIF1AHTR7ALDH1A1 | |
| Erastin SCHEMBL4457820 | 0.88 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNA | |
| Erastin SCHEMBL31385520 | 0.88 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNA | |
| Erastin SCHEMBL22213543 | 0.88 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344029-B2 | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | WASHINGTON UNIVERSITY (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190002457-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | WASHINGTON UNIVERSITY | 2019-01-03 | — | — | US | disclosed |
| US-20170015660-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015660-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | SIGMAR1, TMEM97, AIFM2 | SLC7A11 22/4885VDAC2 2807/4885HIF1A 1446/4885 |
| US-20190002457-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | SIGMAR1, TMEM97, AIFM2 | SLC7A11 22/4885VDAC2 2807/4885HIF1A 1446/4885 |
| US-10344029-B2 | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | SIGMAR1, TMEM97, FFAR2 | SLC7A11 2569/4885VDAC2 4750/4885HIF1A 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.